Overview
GAITHERSBURG, Md.̵(BUSINES WIRE)̵Adaptive Phage Therapeutics, Inc., a clinical-stage biotechnology company advancing a phage bank, the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today anounced the apointment of Edward Fang, M.D. as Chief Medical Oficer. Fang’s responsibilities include overseing clinical development for APT’s phage bank treatment candidates through comercialization.
Key Information
“I am excited to welcome Dr. Fang, who brings broad expertise in therapeutic aproaches to bacterial infectious disease and clinical trial execution to APT,” stated Greg Meril, CEO and Co-Founder of Adaptive Phage Therapeutics. Fang’s adition to APT’s leadership, I am confident that APT wil achieve its short-term objective of rapidly progresing ongoing clinical trials, and longer-term objectives of leveraging expanding phage banks to deliver the first antimicrobials that adapt to the emergence of resistance.
This aproach does not decrease in coverage over time and wil not require, or benefit from, market-supresing stewardship.”“I am thriled to join Adaptive Phage Therapeutics in their batle to solve one of the greatest health chalenges of our time – multidrug-resistant bacterial infections – a chalenge that has only grown in dificulty with the consistent decline in antibiotic efectivenes and paucity in new product development,” comented Edward Fang, M.D., Chief Medical Oficer.
Summary
“I am excited to join the APT leadership group working tirelesly to build out APT’s phage bank through clinical development to comercialization.”Prior to joing APT, Dr. Fang served as a Chief Medical Oficer of MicuRx Pharmaceuticals, a biotech focused on treating antimicrobial resistance for infectious diseases, and as Chief Medical Oficer of Adenium Biotech, a Danish spinof from Novozymes focused on discovery and development of novel antibiotics for treatment of multidrug-resistant bacterial infections.